Cargando…
Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study
BACKGROUND: Accurate identification of pCR to neoadjuvant chemotherapy (NAC) is essential for determining appropriate surgery strategy and guiding resection extent in breast cancer. However, a non-invasive tool to predict pCR accurately is lacking. Our study aims to develop ensemble learning models...
Autores principales: | Huang, YuHong, Zhu, Teng, Zhang, XiaoLing, Li, Wei, Zheng, XingXing, Cheng, MinYi, Ji, Fei, Zhang, LiuLu, Yang, CiQiu, Wu, ZhiYong, Ye, GuoLin, Lin, Ying, Wang, Kun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050775/ https://www.ncbi.nlm.nih.gov/pubmed/37007742 http://dx.doi.org/10.1016/j.eclinm.2023.101899 |
Ejemplares similares
-
Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer
por: Lei, Chuqian, et al.
Publicado: (2020) -
Measurement of molecular biomarkers that predict the tumor response in estrogen receptor-positive breast cancers after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy
por: Zhu, Teng, et al.
Publicado: (2017) -
Erratum: Analysis of Tau Protein Expression in Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Different Molecular Subtypes of Breast Cancer
por: Lei, Chuqian, et al.
Publicado: (2020) -
Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial
por: Yang, Ciqiu, et al.
Publicado: (2022) -
Multiparametric MRI-based radiomics analysis for the prediction of breast tumor regression patterns after neoadjuvant chemotherapy
por: Zhuang, Xiaosheng, et al.
Publicado: (2020)